
ARCH Venture Partners raises close to $3B for early-stage biotech fund – GeekWire
ARCH Venture Partners has closed a $2.975 billion fund targeted for early-stage biotech companies. The firm’s 12th venture fund comes on the heels of a nearly $2 billion fund announced in January 2021 and launches amidst a biotech bear market.